Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes

European Journal of Immunology

Volumn 36, Issue 5, 2006, Pages 1267-1274

  Riemer, Angelika B ^a,b   Förster Waldl, Elisabeth ^a   Brämswig, Kira H ^a   Pollak, Arnold ^a   Zielinski, Christoph C ^a   Pehamberger, Hubert ^b   Lode, Holger N ^c   Scheiner, Otto ^a   Jensen Jarolim, Erika ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer vaccine; Ch14.18; Disialoganglioside GD2; Epitope mimic; Tumor associated carbohydrate antigen

Indexed keywords

CANCER VACCINE; CARBOHYDRATE; EPITOPE; GANGLIOSIDE GD2; IMMUNOGLOBULIN G ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE DERIVATIVE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CROSS REACTIONS; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN G; MELANOMA; MICE; MICE, INBRED BALB C; NEUROBLASTOMA; VACCINATION;

EID: 33646594753     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200535279     Document Type: Article

References (45)

1. Hakomori, S., Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001. 491: 369-402.
2. Ritter, G. and Livingston, P. O., Ganglioside antigens expressed by human cancer cells. Semin. Cancer Biol. 1991. 2: 401-409.
3. Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O. and Livingston, P. O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 1997. 73: 42-49.
4. Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A., Staffileno, L. K. and Reisfeld, R. A., Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984. 44: 5914-5920.
5. Cheung, N. K., Saarinen, U. M., Neely, J. E., Landmeier, B., Donovan, D. and Coccia, P. F., Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985. 45: 2642-2649.
6. Xiao, W. H., Yu, A. L. and Sorkin, L. S., Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 1997. 69: 145-151.
7. Cheresh, D. A., Harper, J. R., Schulz, G. and Reisfeld, R. A., Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc. Natl. Acad. Sci. USA 1984. 81: 5767-5771.
8. Cheresh, D. A., Rosenberg, J., Mujoo, K., Hirschowitz, L. and Reisfeld, R. A., Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res. 1986. 46: 5112-5118.
9. Saito, M., Yu, R. K. and Cheung, N. K., Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem. Biophys. Res. Commun. 1985. 127: 1-7.
10. Cheung, N. K., Kushner, B. H., Cheung, I. Y., Kramer, K., Canete, A., Gerald, W., Bonilla, M. A. et al., Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol. 1998. 16: 3053-3060.
11. Kramer, K., Gerald, W. L., Kushner, B. H., Larson, S. M., Hameed, M. and Cheung, N. K., Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med. Pediatr. Oncol. 2001. 36: 194-196.
12. Mujoo, K., Cheresh, D. A., Yang, H. M. and Reisfeld, R. A., Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987. 47: 1098-1104.
13. Mueller, B. M., Romerdahl, C. A., Gillies, S. D. and Reisfeld, R. A., Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 1990. 144: 1382-1386.
14. Kendra, K., Malkovska, V., Allen, M., Guzman, J. and Albertini, M., In vivo binding and antitumor activity of ch14.18. J. Immunother. 1999. 22: 423-430.
15. Raffaghello, L., Marimpietri, D., Pagnan, G., Pastorino, F., Cosimo, E., Brignole, C., Ponzoni, M. and Montaldo, P. G., Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett. 2003. 197: 205-209.
16. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Allen, L., Tilden, A. B., Grizzle, W., Reisfeld, R. A. et al., Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum. Antibodies Hybridomas 1992. 3: 19-24.
17. Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P. et al., A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer 1995. 31A: 261-267.
18. Yu, A. L., Uttenreuther-Fischer, M. M., Huang, C. S., Tsui, C. C., Gillies, S. D., Reisfeld, R. A. and Kung, F. H., Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 1998. 16: 2169-2180.
19. Murray, J. L., Kleinerman, E. S., Jia, S. F., Rosenblum, M. G., Eton, O., Buzaid, A., Legha, S. et al., Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J. Immunother. Emphasis Tumor Immunol. 1996. 19: 206-217.
20. Ozkaynak, M. F., Sondel, P. M., Krailo, M. D., Gan, J., Javorsky, B., Reisfeld, R. A., Matthay, K. K. et al., Phase I study of chimeric human/ murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J. Clin. Oncol. 2000. 18: 4077-4085.
21. Albertini, M. R., Hank, J. A., Schiller, J. H., Khorsand, M., Borchert, A. A. Gan, J., Bechhofer, R. et al., Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res. 1997. 3: 1277-1288.
22. Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D. and Reisfeld, R. A., Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 1997. 89: 1586-1594.
23. King, D. M., Albertini, M. R., Schalch, H., Hank, J. A., Gan, J., Surfus, J., Mahvi, D. et al., Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 2004. 22: 4463-4473.
24. Zhang, H., Zhang, S., Cheung, N. K., Ragupathi, G. and Livingston, P. O., Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998. 58: 2844-2849.
25. Förster-Waldl, E., Riemer, A. B., Dehof, A. K, Neumann, D., Bramswig, K., Boltz-Nitulescu, G., Pehamberger, H. et al., Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol. 2005. 42: 319-325.
26. Saleh, M. N., Stapleton, J. D., Khazaeli, M. B. and LoBuglio, A. F., Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J. Immunol. 1993. 151: 3390-3398.
27. Foon, K. A., Sen, G., Hutchins, L., Kashala, O. L, Baral, R., Banerjee, M., Chakraborty, M. et al., Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin. Cancer Res. 1998. 4: 1117-1124.
28. Basak, S., Birebent B., Purev, E., Somasundaram, R., Maruyama, H., Zaloudik, J., Swoboda, R. et al., Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer. Immunol. Immunother. 2003. 52: 145-154.
29. Livingston, P. O., Ritter, G. and Calves, M. J., Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol. Immunother. 1989. 29: 179-184.
30. Portoukalian, J., Carrel, S., Dore, J. F. and Rumke, P., Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group. Int. J. Cancer 1991. 49: 893-899.
31. Ragupathi G., Livingston, P. O., Hood, C., Gathuru, J., Krown, S. E., Chapman, P. B., Wolchok, J. D. et al., Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 2003. 9: 5214-5220.
32. Foon, K. A., Lutzky, J., Baral, R. N., Yannelli, J. R., Hutchins, L., Teitelbaum, A., Kashala, O. L. et al., Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 2000. 18: 376-384.
33. Scott, J. K. and Smith, G. P., Searching for peptide ligands with an epitope library. Science 1990. 249: 386-390.
34. Oldenburg, K. R., Loganathan, D., Goldstein, I. J., Schultz, P. G. and Gallop, M. A., Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Natl. Acad. Sci. USA 1992. 89: 5393-5397.
35. Hoess, R., Brinkmann, U., Handel, T. and Pastan, I., Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993. 128: 43-49.
36. Phalipon, A., Folgori, A., Arondel, J., Sgaramella, G., Fortugno, P., Cortese, R., Sansonetti, P. J. and Felici, F., Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur. J. Immunol. 1997. 27: 2620-2625.
37. Parmley, S. F. and Smith, G. P., Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988. 73: 305-318.
38. Riemer, A. B., Klinger, M., Wagner, S., Bernhaus, A., Mazzucchelli, L., Pehamberger, H., Scheiner, O. et al., Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/ neu. J. Immunol. 2004. 173: 394-401.
39. Riemer, A. B., Hantusch, B., Sponer, B., Kraml, G., Hafner, C., Zielinski, C. C., Scheiner, O. et al., High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol. Immunother. 2005. 54: 677-684.
40. Kieber-Emmons, T., Luo, P., Qiu, J., Agadjanyan, M., Carey, L., Hutchins, W., Westerink, M. A. and Steplewski, Z., Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Hybridoma 1997. 16: 3-10.
41. Kieber-Emmons, T., Luo, P., Qiu, J., Chang, T. Y., O, I., Blaszczyk-Thurin, M. and Steplewski, Z., Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat. Biotechnol. 1999. 17. 660-665.
42. Monzavi-Karbassi B., Cunto-Amesty, G., Luo, P. and Kieber-Emmons, T., Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol. 2002. 20: 207-214.
43. Hou, Y. and Gu, X. X., Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates. J. Immunol. 2003. 170: 4373-4379.
44. Kieber-Emmons, T., Monzavi-Karbassi, B., Wang, B., Luo, P. and Weiner, D. B., Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J. Immunol. 2000. 165: 623-627.
45. Bolesta, E., Kowalczyk A., Wierzbicki, A., Rotkiewicz, P., Bambach, B., Tsao, C. Y., Horwacik, I. et al., DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 2005. 65: 3410-3418.